News | November 11, 2013

Biotronik Receives CE Mark for PK Papyrus Covered Coronary Stent for Perforations

PK Papyrus may provide greater flexibility and reduced crossing profile compared to competition

stents cath lab biotronik pk papyrus
November 11, 2013 — Biotronik announced that the PK Papyrus covered coronary stent system has received CE mark for the treatment of acute coronary artery perforation.
 
According to Biotronik, PK Papyrus boasts 58 percent greater flexibility than Abbott's Jostent Graftmaster due to its "electrospun" membrane. The enhanced electrospinning technology allows for a proprietary single-layer covered stent design rather than the traditional "sandwich technique" used on comparable stents on the market. The single-layer covered stent design, with its 90 ?m polyurethane membrane, further enables a 24 percent lower crossing profile in comparison to Abbott's Jostent Graftmaster, combining high flexibility and a low crossing profile for exceptional deliverability while sealing vessel defects in acute situations.
 
Many current covered stent designs require large French size guide catheters. Switching guide cathethers can cost the physician valuable time, delaying treatments. PK Papyrus is 5 and 6 French compatible, thereby eliminating the need to switch access catheters during these emergency situations.
 
"In acute situations when there is a vessel perforation, I need a stent that is highly effective and has optimum deliverability,” said Georg Nickenig, M.D., Ph.D., professor and chief, Department of Cardiology, University Hospital Bonn in Bonn, Germany. “With PK Papyrus, I am confident that, if such a situation arises, I have a stent that is straight-forward to introduce into the artery with a flexibility that means simplified placement."
 
While PK Papyrus is based on the same proven Orsiro/PRO-Kinetic Energy stent platform, the wide size range (diameter: 2.5-5 mm, length: 15-26 mm) enables a broad range of vessels to be treated confidently and efficiently.
 
For more information: www.biotronik.com

Related Content

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init